Pages that link to "Q34236634"

The following pages link to Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats (Q34236634):

Displaying 22 items.

• Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models (Q21129461) (← links)
• Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion (Q27325106) (← links)
• From pan-reactive KV7 channel opener to subtype selective opener/inhibitor by addition of a methyl group (Q28539924) (← links)
• Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH₃ in an immune-mediated neurodevelopmental disruption model (Q30405706) (← links)
• GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism (Q30421260) (← links)
• The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue (Q30437188) (← links)
• Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAA receptors containing the α5 subunit (Q34540561) (← links)
• A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude) (Q34661183) (← links)
• The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia (Q36088364) (← links)
• Enhancement of postsynaptic GABAA and extrasynaptic NMDA receptor-mediated responses in the barrel cortex of Mecp2-null mice (Q36729733) (← links)
• Neural oscillations during non-rapid eye movement sleep as biomarkers of circuit dysfunction in schizophrenia (Q38203026) (← links)
• The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia (Q38526546) (← links)
• Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review (Q38618630) (← links)
• Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation (Q38820476) (← links)
• MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs (Q41456540) (← links)
• GABAA receptor subunit deregulation in the hippocampus of human foetuses with Down syndrome (Q47371832) (← links)
• Short-Term Exposure to Enriched Environment in Adult Rats Restores MK-801-Induced Cognitive Deficits and GABAergic Interneuron Immunoreactivity Loss (Q47932301) (← links)
• Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat. (Q47932815) (← links)
• In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia (Q50684220) (← links)
• Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission. (Q52645959) (← links)
• GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. (Q53428761) (← links)
• Quercetin Reduces Cortical GABAergic Transmission and Alleviates MK-801-Induced Hyperactivity. (Q64970477) (← links)